ReviewMedChemComm2019
Recent advances in the genome mining of
Review in MedChemComm, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Activation of hamiformamide production in the thermotolerant fungus Hamigera avellanea triggered by co-culture with animal immune cells.The Journal of antibiotics · 2026Article
- Topoisomerase II-Like variants enhance acid tolerance and low-pH l-malic acid biosynthesis in metabolic engineeredSynthetic and systems biotechnology · 2026Article
- Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds.International journal of molecular sciences · 2025Review
- Genomic insights into biosynthetic gene cluster diversity and structural variability in marine bacteria.Scientific reports · 2025Article
- Article
- Quantitative Characterization of Gene Regulatory Circuits Associated With Fungal Secondary Metabolism to Discover Novel Natural Products.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Comparative metabolomics study on the secondary metabolites of the red alga,RSC advances · 2024Article
- Bioprospecting ofFrontiers in microbiology · 2024Review
- A heterologous expression platform inChemical science · 2023Article
- Estragole Inhibits Growth and Aflatoxin Biosynthesis ofMicrobiology spectrum · 2023Article
- Expanding the Chemical Diversity of Secondary Metabolites Produced by Two Marine-Derived Enterocin- and Wailupemycin-ProducingACS omega · 2023Article
- Production of L-Malic Acid by Metabolically EngineeredJournal of fungi (Basel, Switzerland) · 2023Article
- Absolute Stereochemistry and Cytotoxic Effects of Vismione E from Marine Sponge-Derived FungusInternational journal of molecular sciences · 2023Article
- Regulation of pseurotin A biosynthesis by GliZ and zinc in Aspergillus fumigatus.Scientific reports · 2023Article
- Lipo-Chitooligosaccharides Induce Specialized Fungal Metabolite Profiles That Modulate Bacterial Growth.mSystems · 2022Article
- Characterization and engineering of the xylose-inducibleMetabolic engineering communications · 2022Article
- Phenyl Ethers from the Marine-Derived FungusACS omega · 2022Article
- Article
- Characterization of a silent azaphilone biosynthesis gene cluster in Aspergillus terreus NIH 2624.Fungal genetics and biology : FG & B · 2022Article
- Production and characterization of a broad-spectrum antimicrobial 5-butyl-2-pyridine carboxylic acid from Aspergillus fumigatus nHF-01.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Secondary metabolites (SMs) produced by filamentous fungi possess diverse bioactivities that make them excellent drug candidates. Whole genome sequencing has revealed that fungi have the capacity to produce a far greater number of SMs than have been isolated, since many of the genes involved in SM biosynthesis are either silent or expressed at very low levels in standard laboratory conditions. There has been significant effort to activate SM biosynthetic genes and link them to their downstream products, as the SMs produced by these "cryptic" pathways offer a promising source for new drug discovery. Further, an understanding of the genes involved in SM biosynthesis facilitates product yield optimization of first-generation molecules and genetic engineering of second-generation analogs. This review covers advances made in genome mining SMs produced by
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.